Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 yr of adjuvant tamoxifen therapy. 1st-line treatment of postmenopausal women w/ hormone receptor +ve or hormone receptor unknown locally advanced or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following antiestrogen therapy.
Adult & elderly 2.5 mg once daily. Duration of treatment: Adjuvant therapy: Continue for 5 years or until tumour relapse occurs, which ever comes first. Metastatic disease: Continue until tumor progression is evident.
Breast cancer in men. Reductions in bone mineral density may occur. Assess bone mineral density eg, DEXA scanning at the start of treatment in women w/, or at risk of osteoporosis; initiate treatment of osteoporosis & carefully monitor patients. Patients w/ CrCl <10 mL/min. Not recommended in childn.